Welcome to our dedicated page for Adaptimmune Therapeutics plc American Depositary Shares news (Ticker: ADAP), a resource for investors and traders seeking the latest updates and insights on Adaptimmune Therapeutics plc American Depositary Shares stock.
Adaptimmune Therapeutics plc (NASDAQ: ADAP) is a clinical-stage biopharmaceutical company focused on the design, development, and delivery of T-cell therapies to treat cancer. Established in 2008, Adaptimmune has grown from a private entity to one of the top biopharmaceutical IPOs in 2015, and its U.S. operations are headquartered in Philadelphia, PA. Using its proprietary T-cell receptor (TCR) platform, Adaptimmune engineers T-cells to target and destroy cancer cells. This innovative approach has led to the development of a robust pipeline of immuno-oncology product candidates primarily aimed at solid tumors.
The company’s leading programs include afami-cel and lete-cel, both engineered T-cell therapies targeting specific cancer antigens. Afami-cel, targeting MAGE-A4, has shown promising results in treating advanced synovial sarcoma, with the U.S. FDA accepting its Biologics License Application (BLA) for priority review. The anticipated approval and commercial launch of afami-cel in 2024 will mark a significant milestone for Adaptimmune, potentially making it the first engineered T-cell therapy for solid tumors available to patients. Lete-cel, targeting NY-ESO-1, is being evaluated for synovial sarcoma and myxoid round cell liposarcoma (MRCLS) in the pivotal IGNYTE-ESO trial. Preliminary results indicate a 40% response rate, meeting the primary efficacy endpoint.
Adaptimmune has formed strategic partnerships to advance its pipeline and enhance its manufacturing capabilities. Recent collaborations include agreements with Galapagos to develop next-generation TCR therapies and a $125 million debt financing deal with Hercules Capital, strengthening its financial position.
In addition to its lead programs, Adaptimmune is advancing a broad clinical and preclinical pipeline, including ADP-A2M4CD8 (uza-cel), targeting a range of solid tumors, and several other next-generation and allogeneic T-cell therapies. The company continues to invest in research and development, with plans to expand its platform and address additional cancer indications.
The company’s commitment to transforming cancer treatment is underpinned by a strategy of bringing novel therapies to market efficiently. With over $300 million in funding and strategic plans extending into 2026, Adaptimmune is well-positioned to achieve significant milestones and make substantial impacts in the field of oncology.
Adaptimmune Therapeutics (NASDAQ: ADAP) reports Q3 2024 updates with Total Liquidity of $186.1 million. The company announces a strategic restructuring with a planned 33% headcount reduction in Q1 2025, targeting approximately $300 million in cost savings over four years. The Tecelra® launch is progressing with 9 Authorized Treatment Centers, and the first patient has been apheresed. The company reports a 42% overall response rate in the lete-cel IGNYTE-ESO pivotal trial for synovial sarcoma and MRCLS. Q3 revenue was $40.9 million, and the company aims to achieve operating breakeven during 2027.
Adaptimmune Therapeutics (NASDAQ: ADAP) announced positive results from its pivotal Phase 2 IGNYTE-ESO trial of lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma (MRCLS). The trial achieved a 42% response rate (27/64 patients), including six complete responses and 21 partial responses. The median duration of response was 18.3 months for synovial sarcoma and 12.2 months for MRCLS. Based on these results, the company plans to initiate a rolling Biologics License Application submission by end of 2025.
Adaptimmune Therapeutics (NASDAQ: ADAP) has announced its participation in three major scientific conferences: SITC (November 6-10, Houston), CTOS (November 13-16, San Diego), and ASH (December 7-10, San Diego). The company will present research on cell therapies for solid tumors, particularly focusing on synovial sarcoma treatments.
Key presentations include data on afami-cel's anti-tumor activity, the IGNYTE-ESO trial results, and decentralized manufacturing processes. A notable virtual event is scheduled for November 18, featuring Dr. Sandra D'Angelo from Memorial Sloan Kettering Cancer Center, discussing the IGNYTE-ESO dataset and engineered cell therapies' impact on sarcoma treatment.
Adaptimmune Therapeutics (NASDAQ: ADAP), a cell therapy company focused on solid tumor cancers, will announce its Q3 2024 financial results and business updates after US markets close on November 13, 2024. The company will host a live webcast at 4:30 p.m. EDT (9:30 p.m. GMT). The press release will be available on Adaptimmune's corporate website, and investors can access the webcast through a provided link. Call-in options are available for US/Canada (+1-844-763-8274) and International (+1-647-484-8814) participants.
Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company focused on redefining solid tumor cancer treatment with cell therapy, has announced its participation in two major investment bank conferences this September:
1. Wells Fargo Healthcare Conference in Boston, MA on September 4, 2024, at 4:30 PM EDT.
2. H.C. Wainwright 26th Annual Global Investment Conference in NYC, NY on September 9, 2024, at 9:50 AM EDT.
Both events will feature fireside chats and will be webcast live on Adaptimmune's website. Replays will be available for a time after the events.
Adaptimmune Therapeutics plc (Nasdaq: ADAP) reported Q2 2024 financial results and business updates. Key highlights include:
1. U.S. FDA approval of Tecelra® (afami-cel), the first engineered cell therapy for solid tumors.
2. Total Liquidity of $214.8 million at the end of Q2.
3. Revenue increased to $128.2 million for Q2 2024, compared to $5.1 million in Q2 2023.
4. Net profit of $69.5 million for Q2 2024, compared to a loss of $21.3 million in Q2 2023.
5. Plans to initiate rolling BLA submission for lete-cel in 2025 and commercial launch in 2026.
6. Projected peak U.S. sales of $400 million for the sarcoma franchise.
Adaptimmune Therapeutics plc (Nasdaq: ADAP), a company focused on redefining solid tumor cancer treatment with cell therapy, has announced it will release its Q2 2024 financial results and business updates on Monday, August 12, 2024, before US markets open. The company will host a live webcast at 8:00 a.m. EDT (1:00 p.m. BST) on the same day to discuss the results.
Investors can access the press release on Adaptimmune's corporate website, and join the webcast at https://www.gowebcasting.com/13404. For those preferring to call in, the numbers are +1-844-763-8274 (US/Canada) or +1-647-484-8814 (International). Participants are advised to dial in 10 minutes before the scheduled start time.
Adaptimmune Therapeutics (NASDAQ: ADAP) has received FDA accelerated approval for TECELRA® (afamitresgene autoleucel), the first engineered cell therapy for a solid tumor approved in the U.S. TECELRA is approved for treating adults with advanced MAGE-A4+ synovial sarcoma who have specific HLA types and have received prior chemotherapy.
Key points:
- First new treatment for synovial sarcoma in over a decade
- 43% overall response rate in the SPEARHEAD-1 trial
- Approval based on response rate and duration; confirmatory trial required
- Adaptimmune plans to onboard ~30 treatment centers within two years
- Companion diagnostics for HLA type and MAGE-A4 expression approved
TECELRA can cause serious side effects, including cytokine release syndrome and neurotoxicity. Adaptimmune will hold a webcast on August 2 to provide additional details.
Adaptimmune Therapeutics (NASDAQ: ADAP) presented interim analysis data from its pivotal IGNYTE-ESO trial at ASCO. The study focuses on lete-cel, an engineered cell therapy targeting NY-ESO-1, in synovial sarcoma (SyS) and myxoid/round cell liposarcoma (MRCLS). The trial achieved a 40% overall response rate (ORR) across both cancer types and a median duration of response (mDOR) of approximately 11 months. These findings reinforce the potential of lete-cel to address unmet medical needs in these sarcoma indications. Full results are expected in late 2024, with a Biologics License Application (BLA) submission planned for 2025. Adaptimmune aims to commercialize afami-cel later this year and lete-cel in 2026.
Adaptimmune and Galapagos have entered a clinical collaboration to evaluate Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer. The trial aims to leverage Galapagos' decentralized manufacturing platform to improve efficacy and durability. Initial trials showed an 80% response rate with partial responses in four out of five patients. Adaptimmune will receive $70M upfront, $30M in R&D funding, and potentially up to $465M in milestone payments, with additional tiered royalties. Galapagos has an option to license uza-cel for global development and commercialization.
FAQ
What is the current stock price of Adaptimmune Therapeutics plc American Depositary Shares (ADAP)?
What is the market cap of Adaptimmune Therapeutics plc American Depositary Shares (ADAP)?
What is Adaptimmune Therapeutics' primary focus?
What are the key programs of Adaptimmune Therapeutics?
What is afami-cel?
When is afami-cel expected to be commercially available?
What is lete-cel?
What are Adaptimmune’s recent strategic collaborations?
Where are Adaptimmune’s U.S. operations based?
What is Adaptimmune’s approach to cancer treatment?
What are the financial projections for Adaptimmune?
How can one get more information about Adaptimmune’s pipeline and operations?
